Insmed (NASDAQ:INSM) Trading Down 3.4% - Time to Sell?

Key Points

• Insmed's stock (NASDAQ: INSM) fell by 3.4% during mid-day trading, marking a significant decline from the previous closing price, with unusually low trading volume.
• Analysts maintain a consensus rating of "Moderate Buy" for Insmed with a consensus price target of $139.86, indicating positive outlook despite recent stock performance.
• The company reported a quarterly loss of ($1.70) earnings per share, missing expectations, but showed an 18.9% increase in revenue year-over-year.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) traded down 3.4% during mid-day trading on Monday . The stock traded as low as $143.84 and last traded at $141.03. 54,412 shares were traded during mid-day trading, a decline of 98% from the average session volume of 2,753,988 shares. The stock had previously closed at $145.93.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Morgan Stanley upped their target price on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Guggenheim upped their price target on shares of Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a report on Monday, September 8th. Citigroup raised shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. UBS Group upped their price target on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Stifel Nicolaus upped their price target on shares of Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $139.86.

Insmed Price Performance

The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $30.26 billion, a price-to-earnings ratio of -25.07 and a beta of 0.97. The stock has a 50-day moving average price of $119.40 and a 200 day moving average price of $92.09.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company's quarterly revenue was up 18.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares of the company's stock, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at $30,035,841.60. This represents a 2.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 248,577 shares of company stock worth $27,137,914 in the last three months. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of INSM. Cullen Frost Bankers Inc. lifted its stake in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP purchased a new position in Insmed in the 4th quarter worth approximately $28,000. ORG Partners LLC lifted its stake in Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 196 shares in the last quarter. Hilltop National Bank purchased a new position in Insmed in the 2nd quarter worth approximately $28,000. Finally, FNY Investment Advisers LLC purchased a new position in Insmed in the 2nd quarter worth approximately $33,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.